Modality
mAb (human IgG1)
Mechanism
IL-17A neutralization
Targets
IL-17A
Storage
refrigerated 2–8 °C
Approved
plaque psoriasis — FDA 2015 · psoriatic arthritis — FDA 2016 · ankylosing spondylitis — FDA 2016 · hidradenitis suppurativa — FDA 2023
In trial
—
Monitoring
TB, IBD screening (caution)
Last verified
2026-04-14
Mechanism of action
Cosentyx label (FDA, 2024)drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug
Monitoring & workup
Baseline workup
- •TB IGRA (or PPD)
- •HBV sAg if high risk; HCV Ab if high risk
- •Update age-appropriate vaccines before start
Ongoing monitoring
- •No routine labs
- •Annual TB screening if high exposure risk
- •IL-17 class: monitor for candida overgrowth + IBD flare
- •IL-23 class: monitor for injection-site reactions